{"analyses":[{"ciLowerLimit":"0.38","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.15","estimateComment":"Reference level is 70.2 Gy arm","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER_LEGACY","pValue":"0.14","paramType":"Hazard Ratio (HR)","paramValue":"0.66","statisticalComment":"Two-sided significance level = 0.05","statisticalMethod":"Gray's test"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.7","upperLimit":"2.5","value":"1.4"},{"groupId":"OG001","lowerLimit":"0.4","upperLimit":"1.8","value":"0.8"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"751"},{"groupId":"OG001","value":"748"}],"units":"Participants"}],"description":"Survival time is defined as time from randomization to the date of death due to prostate cancer and is estimated by the cumulative incidence method. Patients last know to be alive are censored at date of last contact. Death due to prostate cancer was defined as primary cause of death certified as due to prostate cancer, or death in association with any of the following conditions: Further clinical tumor progression occurring after initiation of salvage anti-tumor therapy, a rise (that exceeds 1.0 ng/ml) in the serum PSA level on at least two consecutive occasions that occurred during or after salvage androgen suppression therapy, or disease progression in the absence of any anti-tumor therapy.","dispersionType":"95% Confidence Interval","groups":[{"description":"70.2 Gy 3D-CRT/IMRT: Radiation will be delivered via 3D conformal radiation therapy (3D-CRT) or intensity modulated radiation therapy (IMRT) in 1.8 Gy minimum dose fractions to a total of 70.2 Gy in 39 fractions. All fields treated once daily, five fractions per week. No more than 2% of the planning target volume and none of the clinical target volume may receive less than 70.2 Gy.","id":"OG000","title":"70.2 Gy"},{"description":"79.2 Gy 3D-CRT/IMRT: Radiation will be delivered via 3D conformal radiation therapy (3D-CRT) or intensity modulated radiation therapy (IMRT) in 1.8 Gy minimum dose fractions to a total of 79.2 Gy in 44 fractions. All fields treated once daily, five fractions per week. No more than 2% of the planning target volume and none of the clinical target volume may receive less than 79.2 Gy.","id":"OG001","title":"79.2 Gy"}],"paramType":"NUMBER","populationDescription":"All eligible patients who did not withdraw consent","reportingStatus":"POSTED","timeFrame":"From randomization to date of failure (death due to prostate cancer) or death from other cause or last follow-up. Analysis occurs at the same time as the primary endpoint.","title":"Disease Specific Survival","type":"SECONDARY","unitOfMeasure":"percentage of participants"}